噻托溴铵联合舒利迭治疗COPD的临床疗效观察  

Study on clinical efficacy of tiotropium bromide combined with seretide in treatment of patients with chronic obstructive pulmonary disease

作　　者：蓝芬[1] 朱卫华[1] 严琼[1] 左斌[1] 钟莹[1] 陈子谓[1] 

机构地区：[1]广州市第十二人民医院呼吸内科,广东广州510620

出　　处：《临床和实验医学杂志》2014年第7期532-534,共3页Journal of Clinical and Experimental Medicine

基　　金：广州市医药卫生科技计划项目;基金编号:201102A213171项目名称:住院吸烟患者的戒烟干预效果及戒烟成功因素的分析

摘　　要：目的探讨噻托溴铵联合舒利迭治疗慢性阻塞性肺疾病(COPD)的临床疗效。方法选取60例COPD患者,随机分为观察组和对照组,对照组仅给予舒利迭,观察组采用噻托溴铵联合舒利迭治疗,比较两组患者第1秒用力呼气容积(FEV1)、第1秒用力呼气容积用力肺活量(FEV1/FVC)、动脉血氧分压(PO2)、二氧化碳分压(PCO2)及临床症状评分。结果采用噻托溴铵联合舒利迭治疗COPD患者,可明显提高FEV1、FEV1/FVC、PO2,降低PCO2和临床症状评分,与单独使用舒利迭相比差异显著(P<0.05)。结论采用噻托溴铵联合舒利迭治疗COPD可有效改善患者肺功能和生活质量,值得临床推广使用。Objective To explore the clinical efficacy of tiotropium bromide combined with seretide in treatment of patients with chronic obstructive pulmonary disease. Methods A total of 60 patients with COPD were randomly divided into two groups. Tiotropium bromide combined with seretide were used in patients of observation group and seretide was used alone in patients of control group. FEV1, FEV1/FVC, PO2 , PCO2 and symptom scores were compared between these two groups. Results FEV1, FEV1/FVC and PO2 in patients of observation group were significantly higher than those of patients in control group, but PCO2 and symptom scores of patients in observation group were significantly lower than those of patients in control group, and the difference between these two groups was significant （ P 〈 0.05 ）. Conclusion The application of tiotropium bromide combined with seretide in treatment of patients with chronic obstructive pulmonary disease can improve the lung function and life quality of these patients, hence it is worthy to be clinically promoted.

关 键 词：慢性阻塞性肺疾病 噻托溴铵 舒利迭 

分 类 号：R563.9[医药卫生—呼吸系统]